Obiltoxaximab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Safety Information

Hazardous Substances Data

1351337-07-9(Hazardous Substances Data)

Obiltoxaximab Usage And Synthesis

Enzyme inhibitor

This anti-anthrax therapeutic (MW = 145.5 kDa; CAS 1351337-07-9; Trade Name = Anthim?) is an FDA-approved mouse/human chimeric monoclonal antibody that binds to protective antigen (Kd = 0.3 nM), blocking the latter’s interaction with host cell anthrax receptor, which mediates the translocation of lethal factor [LF] and edema factor into the host cell cytoplasm (See Anthrax Lethal Toxin). Anthim is recommended for the treatment (when combined with antibacterial drugs, such as levofloxacin, ciprofloxacin and doxycycline) and prophylactically (when used alone) treat inhalational anthrax (i.e., exposure to Bacillus anthracis spores. Obiltoxaximab was been designed to neutralize the free protective antigen of B. anthracis, thereby inhibiting the lethal effects of anthrax toxins. Inasmuch as it would be unethical to conduct clinical trials in humans with clinically inducced inhalational anthrax, Anthim’s efficacy was evaluated in NZW rabbits and cynomolgus macaques. See also JMV 390-1

Obiltoxaximab(1351337-07-9)Related Product Information

• Voxalatamab
• Zanidatamab
• Ansuvimab
• Vantictumab
• Ralpancizumab
• Cabiralizumab
• Rulonilimab
• Votumumab
• Tarcocimab
• Samalizumab